Abstract
The purpose of this study was to determine the feasibility of applying accelerated in vitro release testing to correlate or predict long-term in vitro release of leuprolide poly(lactideco-glycolide) microspheres. Peptide release was studied using a dialysis technique at 37°C and at elevated temperatures (50°C–60°C) in 0.1 M phosphate buffered saline (PBS) pH 7.4 and 0.1 M acetate buffer pH 4.0. The data were analyzed using a modification, of the Weibull equation. Peptide release was temperature dependent and complete within 30 days at 37°C and 3 to 5 days at the elevated temperatures. In vitro release profiles at the elevated temperatures correlated well with release at 37°C. The shapes of the release profiles at all temperatures were similar. Using the modified Weibull equation, an increase in temperature was characterized by an increase in the model parameter, α, a scaling factor for the apparent rate constant. Complete release at 37°C was shortened from ∼30 days to 5 days at 50°C, 3.5 days at 55°C, 2.25 days at 60°C in PBS pH 7.4, and 3 days at 50°C in acetate buffer pH 4.0. Values for the model parameter β indicated that the shape of the release profiles at 55°C in PBS pH 7.4 (2.740) and 50°C in 0.1 M acetate buffer pH 4.0 (2.711) were similar to that at 37°C (2.577). The Ea for hydration and erosion were determined to be 42.3 and 19.4 kcal/mol, respectively. Polymer degradation was also temperature dependent and had an Ea of 31.6 kcal/mol. Short-term in vitro release studies offer the possibility of correlation with long-term release, thereby reducing the time and expense associated with longterm studies. Accelerated release methodology could be useful in the prediction of long-term release from extended release microsphere dosage forms and may serve as a quality control tool for the release of clinical or commercial batches.
Keywords: biodegradable microspheres, accelerated in vitro release, modified Weibull equation, sigmoidal triphasic release
Full Text
The Full Text of this article is available as a PDF (521.4 KB).
Footnotes
Selected for the 2005 AAPS Outstanding Graduate Student Research Award in Pharmaceutical Technologies Sponsored by Solvay Pharmaceuticals.
References
- 1.Ramstack M, Grandolfi G, Mannaert E, D’Hoore P, Lasser RA. Long-acting risperidone: prolonged-release injectable delivery of risperidone using Medisorb microsphere technology. Abstracts of the IXth International Congress on Schizophrenia Research. Schizophrenia Research. 2003;60:314–314. doi: 10.1016/S0920-9964(03)80260-8. [DOI] [Google Scholar]
- 2.Kostanski JW, Thanoo BC, DeLuca PP. Preparation, characterization, and in vitro evaluation of 1- and 4-month controlled release orntide PLA and PLGA microspheres. Pharm Dev Technol. 2000;5:585–596. doi: 10.1081/PDT-100102043. [DOI] [PubMed] [Google Scholar]
- 3.D’Souza SS, Selmin F, Murty SB, Qiu W, Thanoo BC, DeLuca PP. Assessment of fertility in male rats after extended chemical castration with a GnRH antagonist. AAPS PharmSci. 2004;6:E10–E10. doi: 10.1208/ps060110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Woo BH, Na K-H, Dani BA, Jiang G, Thanoo BC, DeLuca PP. In vitro characterization and in vivo testosterone suppression of 6-month release poly(D,L-lactide) leuprolide microspheres. Pharm Res. 2002;19:546–550. doi: 10.1023/A:1015168301339. [DOI] [PubMed] [Google Scholar]
- 5.Okada H, Doken Y, Ogawa Y, Toguchi H. Preparation of three-month injectable micro spheres of leuprorelin acetate using biodegradable polymers. Pharm, Res. 1994;11:1143–1147. doi: 10.1023/A:1018936815654. [DOI] [PubMed] [Google Scholar]
- 6.Kane JM, Eerdekens M, Lindenmayer J-P, Keith SJ, Lesem M, Karcher K. Long-acting injectable Risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160:1125–1132. doi: 10.1176/appi.ajp.160.6.1125. [DOI] [PubMed] [Google Scholar]
- 7.Siewert M, Dressman J, Brown CK, Shah VP. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech. 2003;4:E7–E7. doi: 10.1208/pt040107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Buchholz B. Accelerated degradation test on resorbable polymers. In: Plank H, Dauner M, Renardy M, editors. Degradation Phenomena of Polymeric Biomaterials. New York, NY: Springer-Verlag; 1992. pp. 67–76. [Google Scholar]
- 9.Makino K, Arakawa M, Kondo T. Preparation and in vitro degradation properties of polylactide microcapsules. Chem Pharm Bull (Tokyo) 1985;33:1195–1201. doi: 10.1248/cpb.33.1195. [DOI] [PubMed] [Google Scholar]
- 10.Bergsma JE, Rozema FR, Bos RRM, Boering G, Joziasse CAP, Pennings AJ. In vitro predegradation at elevated temperatures of poly(lactide) J Mater Sci Mater Med. 1995;6:642–646. doi: 10.1007/BF00123445. [DOI] [Google Scholar]
- 11.Reed AM, Gilding DK. Biodegradable polymers for use in surgery-poly(glycolic)/poly(lactic acid) homo and copolymers. 2. In vitro degradation. Polym. 1981;22:494–498. doi: 10.1016/0032-3861(81)90168-3. [DOI] [Google Scholar]
- 12.Agarwal CM, Huang D, Schmitz JP, Athanasiou KA. Elevated temperature degradation of a 50∶50 copolymer of PLA-PGA. Tissue Eng. 1997;3:345–352. doi: 10.1089/ten.1997.3.345. [DOI] [Google Scholar]
- 13.Hakkarainen M, Albertsson A-C, Karlsson S. Weight losses and molecular weight changes correlated with the evolution of hydroxyacids in simulated in vivo degradation of homo- and copolymers of PLA and PGA. Polym Degrad Stabil. 1996;52:283–291. doi: 10.1016/0141-3910(96)00009-2. [DOI] [Google Scholar]
- 14.Shameem M, Lee H, DeLuca PP. A short term (accelerated release) approach to evaluate peptide release from PLGA depot-formulations. AAPS PharmSci. 1999;1:E7–E7. doi: 10.1208/ps010307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.D’Souza SS, DeLuca PP. Development of a dialysis in vitro release method for biodegradable microspheres. AAPS PharmSciTech. 2005;6:E42–E42. doi: 10.1208/pt060109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Rescigno A. Bioequivalence. Pharm Res. 1992;9:925–928. doi: 10.1023/A:1015809201503. [DOI] [PubMed] [Google Scholar]
- 17.Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–133. doi: 10.1016/S0928-0987(01)00095-1. [DOI] [PubMed] [Google Scholar]
- 18.Polli JE, Rekhi GS, Augsburger LL, Shah VP. Methods to compare dissolution profiles and a rational for wide dissolution specifications for metoprolol tartrate tablets. J Pharm Sci. 1997;86:690–700. doi: 10.1021/js960473x. [DOI] [PubMed] [Google Scholar]
- 19.Sathe PM, Tsong Y, Shah VP. In vitro dissolution profile comparison: statistics and analysis, model dependent approach. Pharm Res. 1996;13:1799–1803. doi: 10.1023/A:1016020822093. [DOI] [PubMed] [Google Scholar]
- 20.Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem. 1931;23:923–931. doi: 10.1021/ie50260a018. [DOI] [Google Scholar]
- 21.Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25–35. doi: 10.1016/0378-5173(83)90064-9. [DOI] [PubMed] [Google Scholar]
- 22.Katzhendler I, Hofman A, Goldberger A, Friedman M. Modeling of drug release from erodible tablets. J Pharm Sci. 1997;86:110–115. doi: 10.1021/js9600538. [DOI] [PubMed] [Google Scholar]
- 23.Langebucher F. Linearization of dissolution rate curves by the Weibull distribution. J Pharm Pharmacol. 1972;27:979–981. doi: 10.1111/j.2042-7158.1972.tb08930.x. [DOI] [PubMed] [Google Scholar]
- 24.Kervinen L, Yliruusi J. Modelling S-shaped dissolution curves. Int J Pharm. 1993;92:115–122. doi: 10.1016/0378-5173(93)90270-P. [DOI] [Google Scholar]